TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
+0.08 (+1.02%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.83
Bid7.90 x 36100
Ask7.96 x 45900
Day's Range7.76 - 8.00
52 Week Range7.67 - 25.96
Avg. Volume18,491,896
Market Cap8.721B
Beta (3Y Monthly)2.46
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • Express Scripts, Novartis subsidiary probed in NJ amid fight over tax credit program
    Yahoo Finance2 days ago

    Express Scripts, Novartis subsidiary probed in NJ amid fight over tax credit program

    Tax breaks for two major health care companies are under scrutiny by New Jersey’s economic development agency.

  • 3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
    Zacks3 days ago

    3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement

    Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.

  • GuruFocus.com3 days ago

    Bernard Horn Comments on Teva Pharmaceutical

    Guru stock highlight Continue reading...

  • Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know
    Zacks4 days ago

    Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know

    Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.11 in the latest trading session, marking a -1.1% move from the prior day.

  • 3 Drug Stocks With Unimaginably Low P/E Ratios
    Motley Fool4 days ago

    3 Drug Stocks With Unimaginably Low P/E Ratios

    These drug developers are all valued at less than four times this year's projected earnings per share.

  • Opioid makers dumped 76 billion pills onto U.S. market over 7 critical years, data shows
    MarketWatch4 days ago

    Opioid makers dumped 76 billion pills onto U.S. market over 7 critical years, data shows

    Newly released federal data shows how drugmakers and distributors increased shipments of opioid painkillers across the U.S. as the nation’s addiction crisis accelerated from 2006 to 2012.

  • Teva Shares Fall Further as Morgan Stanley Downgrades Rating
    Zacks5 days ago

    Teva Shares Fall Further as Morgan Stanley Downgrades Rating

    Shares of Teva (TEVA) are on a downtrend on the risk of high litigation costs related to opioid epidemic in the United States. Morgan Stanley downgrades its rating on Teva.

  • Benzinga5 days ago

    Option Trader Makes Bullish Bet On Lannett Rebound

    On Tuesday morning, Benzinga Pro subscribers received two options alerts related to Lannett. At 9:36 a.m., a trader bought 854 Lannett call options at a $7.50 strike price that expire on Sept. 20. At 9:42 a.m., likely the same trader bought another 752 Sept. 20 $7.50 Lannett call options at the ask price of 45.1 cents.

  • Zacks5 days ago

    J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View

    J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.

  • Teva Pharmaceuticals News: Why TEVA Stock Is Sliding Today
    InvestorPlace6 days ago

    Teva Pharmaceuticals News: Why TEVA Stock Is Sliding Today

    Teva Pharmaceuticals (NYSE:TEVA) is having a Monday of nightmares as some of the company's products have led to lawsuits, which brought about a major analyst downgrade, causing TEVA stock to plummet early in the week.Source: Shutterstock The Israel-based pharma business with a global reach suffered today as the company's opioid-linked litigation has only started to kick off, with thousands of new lawsuits on the horizon. The harmful painkillers recently led to a judge giving the green light for an $85 million settlement in the state of Oklahoma, ensuring that the company will not promote opioids in the state.This is only the tip of the iceberg for Teva, which had a Monday that saw Morgan Stanley lower the stock's rating from an Equal Weight to an Underweight. The firm added that its price target on TEVA stock has now decreased from $16 per share to $6 per share.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMorgan Stanley analyst David Risinger noted that the pharmaceutical giant, as well as competitors such as Endo International PLC (NASDAQ:ENDP), are experiencing "underappreciated risks" coming from buying group pressure, which are now more negative than predicted.These include a rise in generic competition, as well as the aforementioned opioid-related suits. The note arrived soon after Argus Capital upped its rating on TEVA stock to a buy with a $12 price target on July 5, 2019.TEVA stock fell 7.5% by day's end, while ENDO stock slid 3.7%. More From InvestorPlace * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond * 7 Dependable Dividend Stocks to Buy * 7 Retail Stocks to Buy for the Second Half of 2019 * 10 Stocks to Sell for an Economic Slowdown The post Teva Pharmaceuticals News: Why TEVA Stock Is Sliding Today appeared first on InvestorPlace.

  • Why Callon Petroleum, Teva Pharmaceutical Industries, and PG&E Slumped Today
    Motley Fool6 days ago

    Why Callon Petroleum, Teva Pharmaceutical Industries, and PG&E Slumped Today

    The indexes didn't make major moves today, but these stocks did.

  • Reuters6 days ago

    UPDATE 4-Opioid 'kingpin' J&J fueled epidemic, Oklahoma argues at trial's end

    Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson to a drug cartel leader as they sought to hold the drugmaker responsible for fueling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis. Lawyers for the state, including Attorney General Mike Hunter, told a judge in Norman, Oklahoma that J&J's "greed" led the drugmaker to carry out a years-long marketing effort that caused "utter confusion" about the addictive painkillers' risks. Brad Beckworth, a lawyer for the state, said J&J knew opioids were harmful, yet minimized the risk of addiction in their marketing, resulting in a surge in overdose deaths as doctors overprescribed the drugs and they flooded the state.

  • Teva Relief Rally Loses Steam After Analyst Downgrade
    Investopedia6 days ago

    Teva Relief Rally Loses Steam After Analyst Downgrade

    Teva Pharmaceutical shares moved lower after Morgan Stanley downgraded the stock to Underweight with a price target of $6 per share.

  • Benzinga6 days ago

    Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns

    Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers. The Analyst Morgan Stanley ...

  • Barrons.com6 days ago

    Teva and Endo Stock Are Falling Because Opioid Suits Aren’t Going Away

    The two generic drugmakers were down Monday morning, with Teva getting the worse of it, after a Morgan Stanley analyst downgraded them both, citing the ongoing litigation over prescription opioid sales.

  • Reuters6 days ago

    Oklahoma, J&J to wrap up first trial over opioid crisis

    Oklahoma's attorney general is expected on Monday to urge a judge to find Johnson & Johnson responsible for flooding the market with painkillers and fueling the U.S. opioid epidemic, as the first trial in nationwide litigation over the drug crisis comes to an end. Lawyers for Attorney General Mike Hunter and J&J are set to deliver closing arguments in state court in Norman, Oklahoma following six weeks of testimony from current and former J&J executives and victims of the epidemic. The Oklahoma case is being closely watched by plaintiffs in other opioid lawsuits, particularly in 1,900 cases pending in Ohio brought largely by cities and counties against J&J and other companies.

  • TheStreet.com6 days ago

    [video]Teva Shares Slump on Opioid Litigation Risk Downgrade From Morgan Stanley

    Shares of Teva Pharmaceuticals fall after the company receives a downgrade from Morgan Stanley amid heightened "litigation risks" related to its involvement in the opioid crisis.

  • Teva buys three buildings in West Chester for its R&D campus
    American City Business Journals9 days ago

    Teva buys three buildings in West Chester for its R&D campus

    Teva Pharmaceuticals USA bought three buildings in West Chester this week that — together with three other adjacent buildings it already owns — will allow the pharmaceutical manufacturer to “firmly establish” a North America research and development campus in Chester County. About 650 employees will be based at Teva in West Chester by the end of 2019, including teams involved in product and device research and development, regulatory affairs, medical affairs and a variety of support functions.

  • 3 Top Value Stocks to Buy in July
    Motley Fool9 days ago

    3 Top Value Stocks to Buy in July

    Looking for a bargain? We've got a few.

  • Amneal (AMRX) Down on Guidance Update & Restructuring Plan
    Zacks10 days ago

    Amneal (AMRX) Down on Guidance Update & Restructuring Plan

    Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.

  • Pfizer Stock Is The Biggest Pharma — But Should You Buy It?
    Investor's Business Daily10 days ago

    Pfizer Stock Is The Biggest Pharma — But Should You Buy It?

    Pfizer stock has run sideways this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?

  • ‘There’s Nothing to Give Them’: The Hunt for Lifesaving Epipens
    Bloomberg11 days ago

    ‘There’s Nothing to Give Them’: The Hunt for Lifesaving Epipens

    (Bloomberg) -- A persistent shortage of Mylan NV’s EpiPen anti-allergy injectors is forcing patients and pharmacists to go to great lengths to get their hands on the lifesaving device.EpiPens, which can help stop a severe or life-threatening allergic reaction, have been hard to get since at least May 2018, when the Food and Drug Administration said the device was in short supply. While other options are available, including an identical lower-priced version of the device from Mylan, consumers have also struggled to secure alternatives thanks to uneven distribution, the reluctance of insurers to pay for similar treatments and uneasiness with unfamiliar products.Even patients who live near numerous pharmacies have been scrambling. Boston resident Justin Klaassen said he drove 45 minutes outside the city earlier this year to find EpiPens for his 7-year-old daughter. Everywhere he called within 10 miles of Boston was out of stock of the device, which carries a list price of more than $600 for a two-pack but has been scarce because of manufacturing problems.“My family has enough money to buy one with insurance, you know, and even two because you want one at school and you want one at home,” Klaassen said. “But there are families out there who can’t even afford one, and then you have the problem finding them.”EpiPens can be especially difficult to track down at the start of a new school year, when sales tend to peak. Teachers and staff in school districts across the U.S. have been trained to use the devices, while few have been shown how to use rivals like Adrenaclick and Auvi-Q. Some parents say that they worry that the few moments needed to get familiar with a new injector could be costly in an emergency.Pharmacists are racing to keep EpiPens on their shelves, scooping up fresh supply whenever they can. Ashley Seyfarth, the owner of New Mexico pharmacy Kare Drug, said she “plays the back-order game,” ordering from her wholesaler as soon as a shipment comes in regardless of whether she has prescriptions that need immediate filling.Steps taken by U.S. regulators in recent weeks suggest that they expect the deficit of EpiPen brand injectors to linger, meaning more headaches likely await parents of students returning to school next month. In June, the FDA said expiration dates for some devices would be extended by four months.Mylan has been providing information about EpiPen production and distribution shortages to the FDA on a weekly basis, said agency spokesman Nathan Arnold. The FDA can’t say when the shortage will end, he said.“The FDA looks at drug shortages on a national scale,” Arnold said. “There may be local shortages in any given area of the United States even when there are not national shortages."Mylan shares declined as much as 5.4% on Wednesday, the largest intraday decline in more than a month. So far this year, the drugmaker’s stock price has fallen by 32%.The current problems finding EpiPens can be traced back to September 2017, when Pfizer Inc.’s Meridian Medical Technologies division, which makes them for Mylan, received a warning from the FDA after allegedly failing to investigate hundreds of complaints about faulty devices.Pfizer spokeswoman Kim Bencker said the company is also frustrated by the unsteady supply and that EpiPens involve a “highly complex and technical” manufacturing process.“Despite our significant efforts, we do anticipate further supply shortages over the coming months,” Bencker said. “Product is routinely shipping, and we are committed to permanently resolving this availability issue as quickly as possible.”Mylan spokeswoman Lauren Kashtan said the company is sending shipments as soon as it receives the product from Meridian and encourages people to call customer relations for assistance in locating alternative pharmacies. The generic injector made by Mylan isn’t offically in shortage, according to the FDA.Production problems have also vexed makers of competing injectors. Amneal Pharmaceuticals Inc. lowered its earnings guidance for 2019 on Wednesday due in part to uncertainty about supplies of its generic version of Adrenaclick.Shares of the company declined as much as 37%, the steepest intraday decline since May 2010. Amneal’s product is also manufactured by Pfizer’s Meridian unit, Amneal spokesman David Belian said.Inventory IssuesPharmacists say that nailing down when they can get more EpiPens has been difficult. Carter High, owner of Best Value Rhome Pharmacy in Texas, said his wholesaler has pushed back the date when more injectors would be available several times.“As a parent, I look at that and think, God I wish I could help them,” High said. “I can’t. There’s nothing to give them because I just can’t get it.”High said he has also had difficulty obtaining Mylan’s generic EpiPens. At times, he said he gave patients epinephrine, the drug delivered by a shot from Mylan’s device, the “old-school way,” with a syringe. He said he tells patients to keep expired EpiPens because it’s “better to have something than nothing.”In the meantime, brand-name EpiPen prescriptions have swooned. After peaking at more than 580,000 in August 2016, there were just 27,000 in May 2019, according to data compiled by Bloomberg Intelligence.Going without an EpiPen can be dangerous for patients like Ashley Spencer, 29. She was eating a strawberry when she went into anaphylaxis on June 23. Her skin was bright red and itchy. Her throat was closing.Spencer, who suffers from a rare autoimmune disease, didn’t have an EpiPen. She’d been waiting for a refill for more than a week when her body developed the new allergy.“I can’t go a week and a half without it because my disease also can cause me to go into anaphylaxis at any time,” Spencer said. EpiPens “are crucial to my life.”“As a parent, I look at that and think, God I wish I could help them...There’s nothing to give them because I just can’t get it.”Insurance companies have sometimes balked at paying for pricier alternatives. High, the Texas pharmacist, said wholesalers “have plenty of Auvi-Q, but at $5,000 a whack, I can’t even get insurance to pay for that.” While some large pharmacy chains have struck agreements with EpiPen competitors to try to alleviate the shortage and reduce patients costs, others have struggled to get insurers to pay for alternatives.“Though there are other things out there, we can’t use them even if we can get our hands on them,” said Seyfarth, the pharmacist in New Mexico.Additionally, a new generic made by Teva Pharmaceutical Industries Ltd. has been difficult to track down, pharmacists say. “I’ve never actually seen Teva’s product in the marketplace,” said Hamilton, New Jersey, pharmacist Eklavya Lalwani.In an earnings call in May, Teva Chief Executive Officer Kare Schultz said the company is “ramping up the volumes” and is distributing its injector to Anda Inc., a supplier the drugmaker owns. “Any pharmacy who needs EpiPen can just call Anda, and they will get it within 24 hours,” Schultz said in May.Teva spokeswoman Kelley Dougherty said the company has no backorders for the product, but both High and Lalwani said it was indicated as out of stock in Anda’s ordering system on July 8.Elsewhere, Sandoz, a division of Swiss drug giant Novartis AG, said on Tuesday that Symjepi epinephrine injections, previously only given in hospitals and clinics, will now be available at pharmacies.Even when insurance covers another brand, some parents like Klaassen, in Boston, have trained their family and friends on Mylan’s device and don’t want to switch. Others such as Erin Malawer, who lives near Washington, switched her 14-year-old son to Auvi-Q but still tries to find at least one EpiPen, because she fears that his friends or teachers might not recognize an alternative device in an emergency.“If you’re looking for an EpiPen, blue and orange tube, and it’s not there, you’re wasting precious seconds that could save a life,” Malawer said.(Updates with Amneal Pharmaceuticals comment in the 17th paragraph.)To contact the author of this story: Myah Ward in New York at mward174@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at, Timothy AnnettFor more articles like this, please visit us at©2019 Bloomberg L.P.

  • EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply
    InvestorPlace11 days ago

    EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply

    It looks like there is no end is sight to the EpiPen shortage and Mylan (NASDAQ:MYL) stock is taking a beating Wednesday on the news.Source: Shutterstock Recent statements from the company note that it continues to expect the EpiPen shortage to continue. This is leaving many parents without a way to purchase the medicine as they prepare for the next school season to begin.The reason behind the EpiPen shortage is that the company had production issues back in 2017. Following these problems, the U.S. Food & Drug Administration (FDA) announced that there was a shortage of the devices in the following year. The FDA still has EpiPens listed as in short supply.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo what exactly can parents do to get around the EpiPen shortage? There's always the option of going with the generic version of the drug, which is also made by Mylan. The FDA does not list this one as being limited in supply.Another option that parents may want to consider are rival products. This includes those made by Teva Pharmaceutical (NYSE:TEVA) or Novartis (NYSE:NVS). However, there are concerns about the difference in using these devices and them not being as recognizable as normal EpiPens, reports Bloomberg. * 7 Retail Stocks to Buy for the Second Half of 2019 The Novartis option may be the best one for parents on a budget. The company is selling a two-pack of adult dosage syringes for $250. This is below the $300 price for a comparable pack of Mylan's generic version, Reuters notes.MYL stock was down 3% as of noon Wednesday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy on College Students' Radars * 7 Retail Stocks to Buy for the Second Half of 2019 * The S&P 500's 5 Best Highest-Yielding Dividend Stocks As of this writing, William White did not hold a position in any of the aforementioned securities.The post EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply appeared first on InvestorPlace.

  • Court Ruling Topples Trump Order, No Price Display in TV Ads
    Zacks11 days ago

    Court Ruling Topples Trump Order, No Price Display in TV Ads

    The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

  • Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
    Zacks11 days ago

    Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset

    Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.